A BILL 
To amend title XVIII of the Social Security Act to require 
certain manufacturers to report drug pricing information 
with respect to drugs under the Medicare program, and 
for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Drug Price Trans-
4
parency Act’’. 
5
03:17 Apr 16, 2019
H2087
2 
•HR 2087 IH
SEC. 2. REQUIRING CERTAIN MANUFACTURERS TO REPORT 
1
DRUG 
PRICING 
INFORMATION 
WITH 
RE-
2
SPECT TO DRUGS UNDER THE MEDICARE 
3
PROGRAM. 
4
(a) IN GENERAL.—Section 1847A of the Social Secu-
5
rity Act (42 U.S.C. 1395w–3a) is amended— 
6
(1) in subsection (b)— 
7
(A) in paragraph (2)(A), by inserting ‘‘or 
8
subsection (f)(2), as applicable’’ before the pe-
9
riod at the end; 
10
(B) in paragraph (3), in the matter pre-
11
ceding subparagraph (A), by inserting ‘‘or sub-
12
section (f)(2), as applicable,’’ before ‘‘deter-
13
mined by’’; and 
14
(C) in paragraph (6)(A), in the matter 
15
preceding clause (i), by inserting ‘‘or subsection 
16
(f)(2), as applicable,’’ before ‘‘determined by’’; 
17
and 
18
(2) in subsection (f)— 
19
(A) by striking ‘‘For requirements’’ and 
20
inserting the following: 
21
‘‘(1) IN GENERAL.—For requirements’’; and 
22
(B) by adding at the end the following new 
23
paragraph: 
24
‘‘(2) MANUFACTURERS
WITHOUT
A
REBATE 
25
AGREEMENT UNDER TITLE XIX.— 
26
03:17 Apr 16, 2019
H2087
3 
•HR 2087 IH
‘‘(A) IN GENERAL.—In the case of a man-
1
ufacturer of a drug or biological described in 
2
subparagraph (C), (E), or (G) of section 
3
1842(o)(1) or in clause (ii) or (iii) of section 
4
1881(b)(14)(B) that does not have a rebate 
5
agreement in effect under section 1927, for cal-
6
endar quarters beginning on or after January 
7
1, 2020, such manufacturer shall report to the 
8
Secretary the information described in sub-
9
section (b)(3)(A)(iii) of such section 1927 with 
10
respect to such drug or biological in a time and 
11
manner specified by the Secretary. 
12
‘‘(B) AUDIT.—Information reported under 
13
subparagraph (A) is subject to audit by the In-
14
spector General of the Department of Health 
15
and Human Services. 
16
‘‘(C) VERIFICATION.—The Secretary may 
17
survey wholesalers and manufacturers that di-
18
rectly distribute drugs described in subpara-
19
graph (A), when necessary, to verify manufac-
20
turer prices and manufacturer’s average sales 
21
prices (including wholesale acquisition cost) if 
22
required to make payment reported under sub-
23
paragraph (A). The Secretary may impose a 
24
civil monetary penalty in an amount not to ex-
25
03:17 Apr 16, 2019
H2087
4 
•HR 2087 IH
ceed $100,000 on a wholesaler, manufacturer, 
1
or direct seller, if the wholesaler, manufacturer, 
2
or direct seller of such a drug refuses a request 
3
for information about charges or prices by the 
4
Secretary in connection with a survey under 
5
this subparagraph or knowingly provides false 
6
information. The provisions of section 1128A 
7
(other than subsections (a) (with respect to 
8
amounts of penalties or additional assessments) 
9
and (b)) shall apply to a civil money penalty 
10
under this subparagraph in the same manner as 
11
such provisions apply to a penalty or proceeding 
12
under section 1128A(a). 
13
‘‘(D) 
CONFIDENTIALITY.—Notwithstand-
14
ing any other provision of law, information dis-
15
closed by manufacturers or wholesalers under 
16
this paragraph (other than the wholesale acqui-
17
sition cost for purposes of carrying out this sec-
18
tion) is confidential and shall not be disclosed 
19
by the Secretary in a form which discloses the 
20
identity of a specific manufacturer or whole-
21
saler or prices charged for drugs by such manu-
22
facturer or wholesaler, except— 
23
‘‘(i) as the Secretary determines to be 
24
necessary to carry out this section (includ-
25
03:17 Apr 16, 2019
H2087
5 
•HR 2087 IH
ing the determination and implementation 
1
of the payment amount), or to carry out 
2
section 1847B; 
3
‘‘(ii) to permit the Comptroller Gen-
4
eral to review the information provided; 
5
and 
6
‘‘(iii) to permit the Director of the 
7
Congressional Budget Office to review the 
8
information provided.’’. 
9
(b) ENFORCEMENT.— 
10
(1) IN GENERAL.—Section 1847A such Act (42 
11
U.S.C. 1395w–3a) is further amended— 
12
(A) in subsection (d)(4)— 
13
(i) in subparagraph (A), by striking 
14
‘‘IN GENERAL’’ and inserting ‘‘MISREPRE-
15
SENTATION’’; 
16
(ii) in subparagraph (B), by striking 
17
‘‘subparagraph (B)’’ and inserting ‘‘sub-
18
paragraph (A), (B), or (C)’’; 
19
(iii) by redesignating subparagraph 
20
(B) as subparagraph (D); and 
21
(iv) by inserting after subparagraph 
22
(A) the following new subparagraphs: 
23
‘‘(B) FAILURE TO PROVIDE TIMELY INFOR-
24
MATION.—If the Secretary determines that a 
25
03:17 Apr 16, 2019
H2087
6 
•HR 2087 IH
manufacturer described in subsection (f)(2) has 
1
failed to report on information described in sec-
2
tion 1927(b)(3)(A)(iii) with respect to a drug or 
3
biological in accordance with such subsection, 
4
the Secretary shall apply a civil money penalty 
5
in an amount of $25,000 for each day the man-
6
ufacturer has failed to report such information 
7
and such amount shall be paid to the Treasury. 
8
‘‘(C) FALSE
INFORMATION.—Any manu-
9
facturer required to submit information under 
10
subsection (f)(2) that knowingly provides false 
11
information is subject to a civil money penalty 
12
in an amount not to exceed $100,000 for each 
13
item of false information. Such civil money pen-
14
alties are in addition to other penalties as may 
15
be prescribed by law.’’; and 
16
(B) in subsection (c)(6)(A), by striking the 
17
period at the end and inserting ‘‘, except that, 
18
for purposes of subsection (f)(2), the Secretary 
19
may, if the Secretary determines appropriate, 
20
exclude repackagers of a drug or biological from 
21
such term.’’. 
22
(2) CONFORMING
EXISTING
MANUFACTURER 
23
REPORTING
PENALTIES.—Section 1927(b)(3)(C)(i) 
24
of such Act (42 U.S.C. 1396r–8(b)(3)(C)(i)) is 
25
03:17 Apr 16, 2019
H2087
7 
•HR 2087 IH
amended by inserting ‘‘(or, for such failures occur-
1
ring on or after January 1, 2020, $25,000)’’ after 
2
‘‘$10,000’’. 
3
(c) REPORT.—Not later than January 1, 2021, the 
4
Inspector General of the Department of Health and 
5
Human Services shall assess and submit to Congress a 
6
report on the accuracy of average sales price information 
7
submitted by manufacturers under section 1847A of the 
8
Social Security Act (42 U.S.C. 1395w–3a). Such report 
9
shall include any recommendations on how to improve the 
10
accuracy of such information. 
11
Æ 
03:17 Apr 16, 2019
H2087
